Substance / Medication

Dimercaprol

Overview

Active Ingredient
dimercaprol
RxNorm CUI
3445

Indications

BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by othe

Labeler: AkornUpdated: 2022-06-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of hepatic insufficiency with the exception of postarsenical jaundice. The drug should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure - A systematic review.
Dobrescu Andreea-Iulia, Ebenberger Agnes, Harlfinger Julia et al. · Sci Total Environ · 2022
PMID: 34844314Meta-AnalysisFull text (PMC)
Dimercaprol-modified mesoporous silica nanoparticles for efficient removal of toxic mercury ions from aqueous solution.
Santhamoorthy Madhappan, Ranganathan Suresh, Fathima Arul Sigamani Lesly et al. · Environ Geochem Health · 2024
PMID: 39196434Other
British anti-Lewisite (dimercaprol): an amazing history.
Vilensky Joel A, Redman Kent · Ann Emerg Med · 2003
PMID: 12605205Other
Dimercaprol attenuates oxidative stress-induced damage of retinal ganglion cells in an in vitro and in vivo model of traumatic optic neuropathy.
Tan Xiangpeng, Han Meiting, Han Mengke et al. · Neuropharmacology · 2025
PMID: 40409536Preclinical
In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol.
le Roux Anandie, Cloete Stephanus J, Petzer Jacobus P et al. · Toxicon · 2025
PMID: 41101741Preclinical
Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson's disease: implication of acrolein and TRPA1.
Shi Liangqin, Lin Yazhou, Jiao Yucheng et al. · Transl Neurodegener · 2021
PMID: 33910636PreclinicalFull text (PMC)
Post-translational Activation of Glutamate Cysteine Ligase with Dimercaprol: A NOVEL MECHANISM OF INHIBITING NEUROINFLAMMATION.
McElroy Pallavi B, Sri Hari Ashwini, Day Brian J et al. · J Biol Chem · 2017
PMID: 28202547PreclinicalFull text (PMC)
Inhibition of bacterial adherence on the surface of stents and bacterial growth in bile by bismuth dimercaprol.
Zhang Hongjun, Tang Javon, Meng Xangwen et al. · Dig Dis Sci · 2005
PMID: 15986852Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dimercaprol (substance)
SNOMED CT
387077001
UMLS CUI
C0012383
RxNorm CUI
3445
Labeler
Akorn

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.